Research inspired by patients, for patients
Most, if not all, cancer is the result of a disruption of the normal process of development & maturation.
We aim to understand how normal differentiation goes awry in the setting of malignancy.
Using this understanding of normal differentiation as a window into new therapeutic targets, our goal is to make the first step along the road of drug discovery.
Developing differentiation therapy for patients with acute myeloid leukemia, and other malignancies.
Identifying the mechanism that links the inhibition of the metabolic enzyme DHODH and pyrimidine starvation with myeloid differentiation.
Understanding normal neutrophil function with an eye to the development of therapy for patients with neutropenia.